Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety
Colleen Annesley(Unknown), Michael C. Jensen(Seattle Children's Hospital), Julie Rivers(Seattle Children's Hospital), Adam J. Lamble(Seattle Children's Hospital), Christopher Brown, Karen Spratt, Corinne Summers(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Olivia Finney(Seattle Children's Hospital), Catherine Lindgren(Unknown), Adam Johnson(Sana Biotechnology (United States)), Julie R. Park(Seattle Children's Hospital)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754